ID 1101

Drug Profile

ID 1101

Alternative Names: Adyvia; ID1101

Latest Information Update: 10 Mar 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Innodia
  • Class Antihyperglycaemics; Branched-chain amino acids; Small molecules
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Obesity

Most Recent Events

  • 17 Jul 2008 Innodia has been acquired by BELLUS Health
  • 05 Dec 2006 Phase-II clinical trials in Obesity in Canada (PO)
  • 08 Apr 2005 Clinical data from a media release have been added to the adverse events and pharmacokinetics sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top